ClinicalTrials.gg

How we know

Every link on this study, and who decided it

The study on the left, the conditions and drugs this site links it to, and on each link the judgments that made or checked it, by day and by judge. The top row is the record itself: each new version seen since tracking began. Dashed lines are links the registry record does not make itself. Select a link to see everything judged on it, or a mark for one decision with its reason and evidence.

8 links0 made here, not in the record15 judgments2 judges (the rules as one: Rule based)1 record change seen
Claude Opus 5.5Rule basedRecord updated on ClinicalTrials.gov
Sep 28Oct 5Oct 12Oct 19Oct 26Nov 2Nov 9Nov 16TodayNCT04495296A Trial to Evaluate Safety,Tolerability,Pharmacokinetics andPreliminary Efficacy ofTST001 in Advanced orMetastatic Solid TumorsTranscenta Therapeutics (HangzPhase 1/Phase 2 · active not rRECORDThe record itselfVersions seen nightly since Sep 25, 2…›Sep 29 · ClinicalTrials.gov record · Version of 2026-09-29Version of 2026-09-29CONDITIONSAdvanced CancerNo longer in the registry's filing›Nov 14 · Rule based · General: a category, not a diseaseGeneral: a category, not a diseaseDRUGSOsemitamabEntry “TST001”, read by our name rule›Nov 2 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedOxaliplatinIntervention entry›Nov 2 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackgroundCapecitabineIntervention entry›Nov 2 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackgroundPaclitaxelIntervention entry›Nov 2 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackgroundGemcitabineIntervention entry›Nov 2 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackgroundCisplatinIntervention entry›Nov 2 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackgroundNivolumabIntervention entry›Nov 2 · Claude Opus 5.5 · Background · partnerNov 18 · Rule based · BackgroundBackground · partner

Times are in your time zone; a day marked “day only” kept no time. The graph scrolls sideways on a narrow screen; every mark is also in the list below.

Osemitamab

From the registry record2 judgments on this link
Role in the study, from the registry to what was judged
RegistryEntry “TST001”the record gives no role
→judged=agrees
How the 2 judgments split100%of judgments with a known value say Tested
Tested · 2

All judgments on this study

WhenLinkJudgeDecisionState
Sep 29The record itselfClinicalTrials.gov recordVersion of 2026-09-29Record change
Nov 2OsemitamabClaude Opus 5.5TestedCurrent
Nov 2OxaliplatinClaude Opus 5.5BackgroundCurrent
Nov 2CapecitabineClaude Opus 5.5BackgroundCurrent
Nov 2PaclitaxelClaude Opus 5.5BackgroundCurrent
Nov 2GemcitabineClaude Opus 5.5BackgroundCurrent
Nov 2CisplatinClaude Opus 5.5BackgroundCurrent
Nov 2NivolumabClaude Opus 5.5Background · partnerCurrent
Nov 14Advanced CancerRule based · condition-kind ruleGeneral: a category, not a diseaseCurrent
Nov 18OsemitamabRule based · role ruleTestedAgrees
Nov 18OxaliplatinRule based · role ruleBackgroundAgrees
Nov 18CapecitabineRule based · role ruleBackgroundAgrees
Nov 18PaclitaxelRule based · role ruleBackgroundAgrees
Nov 18GemcitabineRule based · role ruleBackgroundAgrees
Nov 18CisplatinRule based · role ruleBackgroundAgrees
Nov 18NivolumabRule based · role ruleBackgroundAgrees

The rules, in plain words

“Rule based” means one of these decided, not a model or a person. Each runs every night over every study.

Which drugs a study tests

Reads each treatment the study lists and the arms it is in. A drug only in the experimental arm is tested. A drug in every arm while something else changes between the arms is given beside it. A drug only in the control arm is the comparator. Placebo, procedures and usual care are known by name.

Where the whole record has been read, that reading's answer replaces the rule's.

How a condition link is counted

For each condition a study is filed under: whether it is the study's own condition at the finest the study states it, a wider one, a general category, or filed by mistake; and whether it is the main condition, a setting the study names, or only how it was filed.

A decision on file for one study overrides it, with who made it and when.